News archive

2016-01-27

altona Diagnostics developed the RealStar® Zika Virus RT-PCR Kit 1.0 for the qualitative detection of Zika virus specific RNA. The in vitro diagnostic test is based on real-time reverse transcriptase/polymerase chain reaction (RT-PCR) technology and contains an Internal Control for reliable diagnostics.

2015-07-22

The RealStar® MERS-CoV RT-PCR Kit U.S. is a real-time reverse transcriptase polymerase chain reaction (rRT-PCR) test for the in vitro qualitative detection of RNA from MERS-CoV in lower respiratory specimens (tracheal aspirate/tracheal secretions) from individuals with signs and symptoms of infection with MERS-CoV in conjunction with epidemiological risk factors. The RealStar® MERS-CoV RT-PCR Kit U.S. consists of two independent assays, one targeting a region upstream of the E gene (upE) and the other targeting open reading frame 1a (orf1a) of the MERS-CoV genome.  Both assays include a heterologous amplification system (Internal Control) to identify possible RT-PCR inhibition and to confirm the integrity of the reagents of the kit.

2015-07-10

We would like to comment on the article by Broadhurst et al. The authors compared the ReEBOV Antigen Rapid Test Kit (Corgenix Inc) with the RealStar® Filovirus Screen RT-PCR Kit 1.0 (altona Diagnostics GmbH) and an in-house developed real-time RT-PCR method referred to as Trombley-assay.

2015-02-25

The RealStar® Influenza S&T RT-PCR Kit 3.0 and the RealStar® Influenza RT-PCR Kit 1.0 facilitate the detection of the drifted influenza A (H3N2) viruses circulating as dominant subtype in the 2014/15 influenza season in Europe:

2014-11-28

The RealStar® Ebolavirus RT-PCR Kit 1.0 is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for WHO has accepted the first Ebola in vitro diagnostic for procurement by United Nations and other partners to Ebola affected countries. The product, RealStar® Filovirus Screen RT-PCR Kit 1.0 manufactured by Altona Diagnostics GmbH, was assessed under an emergency quality assessment mechanism established by WHO to address the lack of Ebola tests, and to fast-track countries’ access to reliable testing options.